Amgen And AstraZeneca Tout Fresh Tezepelumab Data
TSLP Inhibitor Impresses For Nasal Polyps
Recently-submitted tezepelumab reduced the annualized asthma exacerbation rate by 86% in a subgroup of patients with severe, uncontrolled asthma and nasal polyps, according to data presented at the European Respiratory Society congress.
You may also be interested in...
AstraZeneca’s creation of a new division does not mean it sees a long-term future for its COVID-19 vaccine.
Having got hold of two COPD drugs from Spain's Almirall in 2014, AstraZeneca has passed Eklira and Duaklir onto old partner Covis Pharma as it focuses on more targeted respiratory therapies.
The company plans to file PT027, a new fixed-dose combination of albuterol and budesonide, in 2022 following two positive Phase III trials showing a benefit on lung function.